• Takeda Pharmaceutical recently secured FDA Priority Review for its oral TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis and outlined extensive oncology data presentations at the October 2026 ESMO Congress, covering late stage assets arcotatug tavatecan and TAK-928 plus real world analyses for ALUNBRIG and FRUZAQLA.
• The combination of a potential new dermatology product and upcoming oncology readouts points to Takeda Pharmaceutical leaning heavily on late stage R&D execution across multiple therapy areas to support future portfolio depth and operational focus.
• We will now look at how Takeda Pharmaceutical’s investment narrative could be influenced by FDA Priority Review for zasocitinib.

Ride this mix of late stage…